

Congress of the United States
House of Representatives
Washington, DC 20515-0552

May 9, 2016

Andy Slavitt
Acting Administrator
Centers for Medicare and Medicaid Services
200 Independence Avenue SW
Washington, DC 20201

Dear Acting Administrator Slavitt,

Last week I joined my colleague, Rep. Richard Neal in raising concerns about the new proposed Part B Drug Payment model through the Center for Medicare and Medicaid Innovation (CMMI). Like many of my colleagues, I support CMMI's mission to test innovative payment and service delivery models to reduce healthcare costs without compromising quality of care.

The letter I co-authored raised concerns and asked for clarification in eleven areas including beneficiary impact, physician impact, and model scope. I want to reiterate the importance of addressing the concerns raised in that correspondence. Absent substantial modifications to the proposal, I urge you to withdraw the proposed rule and engage physician groups, patient groups, and life-sciences organizations to craft a new proposal that ensures patient access to the medicines they need.

Sincerely,



Scott Peters
Member of Congress